Pre-order Enquiry
Request Free Sample
United States Alzheimer's Disease Therapeutics and Diagnostics Market Report & Forecast 2021-2027
SKU ID : QYR-19473151 | Publishing Date : 04-Nov-2021 | No. of pages : 93
Detailed TOC of United States Alzheimer's Disease Therapeutics and Diagnostics Market Report & Forecast 2021-2027
1 Introduction to Research & Analysis Reports1.1 Alzheimer's Disease Therapeutics and Diagnostics Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Alzheimer's Disease Therapeutics and Diagnostics Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Alzheimer's Disease Therapeutics and Diagnostics Overall Market Size
2.1 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size: 2021 VS 2027
2.2 United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Alzheimer's Disease Therapeutics and Diagnostics Players in United States Market
3.2 Top United States Alzheimer's Disease Therapeutics and Diagnostics Companies Ranked by Revenue
3.3 United States Alzheimer's Disease Therapeutics and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Alzheimer's Disease Therapeutics and Diagnostics Companies in United States Market, by Revenue in 2020
3.5 Companies Alzheimer's Disease Therapeutics and Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Alzheimer's Disease Therapeutics and Diagnostics Players in United States Market
3.6.1 List of Tier 1 Alzheimer's Disease Therapeutics and Diagnostics Companies in United States
3.6.2 List of Tier 2 and Tier 3 Alzheimer's Disease Therapeutics and Diagnostics Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Market Size Markets, 2021 & 2027
4.1.2 Biomarkers
4.1.3 Cholinesterase inhibitors
4.1.4 NMDA receptor antagonists
4.1.5 Brain imaging
4.1.6 Blood tests
4.2 By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue & Forecasts
4.2.1 By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, 2016-2021
4.2.2 By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, 2022-2027
4.2.3 By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Market Size, 2021 & 2027
5.1.2 Drugs Market
5.1.3 Diagnostics Market
5.2 By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue & Forecasts
5.2.1 By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, 2016-2021
5.2.2 By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, 2022-2027
5.2.3 By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share, 2016-2027
6 Alzheimer's Disease Therapeutics and Diagnostics Companies Profiles
6.1 Namenda
6.1.1 Namenda Company Details
6.1.2 Namenda Business Overview
6.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.1.4 Namenda Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.1.5 Namenda Recent Developments
6.2 Aricept
6.2.1 Aricept Company Details
6.2.2 Aricept Business Overview
6.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.2.4 Aricept Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.2.5 Aricept Recent Developments
6.3 Exelon
6.3.1 Exelon Company Details
6.3.2 Exelon Business Overview
6.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.3.4 Exelon Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.3.5 Exelon Recent Developments
6.4 Solanezumab
6.4.1 Solanezumab Company Details
6.4.2 Solanezumab Business Overview
6.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.4.4 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.4.5 Solanezumab Recent Developments
6.5 Gantenerumab
6.5.1 Gantenerumab Company Details
6.5.2 Gantenerumab Business Overview
6.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.5.4 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.5.5 Gantenerumab Recent Developments
6.6 Verubecestat
6.6.1 Verubecestat Company Details
6.6.2 Verubecestat Business Overview
6.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.6.4 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.6.5 Verubecestat Recent Developments
6.7 Pfizer
6.7.1 Pfizer Company Details
6.7.2 Pfizer Business Overview
6.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.7.4 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.7.5 Pfizer Recent Developments
6.8 Eisai
6.8.1 Eisai Company Details
6.8.2 Eisai Business Overview
6.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.8.4 Eisai Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.8.5 Eisai Recent Developments
6.9 Actavis
6.9.1 Actavis Company Details
6.9.2 Actavis Business Overview
6.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.9.4 Actavis Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.9.5 Actavis Recent Developments
6.10 Lundbeck
6.10.1 Lundbeck Company Details
6.10.2 Lundbeck Business Overview
6.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.10.4 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.10.5 Lundbeck Recent Developments
6.11 Daiichi Sankyo
6.11.1 Daiichi Sankyo Company Details
6.11.2 Daiichi Sankyo Business Overview
6.11.3 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.11.4 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.11.5 Daiichi Sankyo Recent Developments
6.12 Novartis
6.12.1 Novartis Company Details
6.12.2 Novartis Business Overview
6.12.3 Novartis Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.12.4 Novartis Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.12.5 Novartis Recent Developments
6.13 TauRx
6.13.1 TauRx Company Details
6.13.2 TauRx Business Overview
6.13.3 TauRx Alzheimer's Disease Therapeutics and Diagnostics Introduction
6.13.4 TauRx Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021)
6.13.5 TauRx Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of Figures, Tables and Charts Available in United States Alzheimer's Disease Therapeutics and Diagnostics Market Report & Forecast 2021-2027
List of TablesTable 1. Alzheimer's Disease Therapeutics and Diagnostics Market Opportunities & Trends in United States Market
Table 2. Alzheimer's Disease Therapeutics and Diagnostics Market Drivers in United States Market
Table 3. Alzheimer's Disease Therapeutics and Diagnostics Market Restraints in United States Market
Table 4. Key Players of Alzheimer's Disease Therapeutics and Diagnostics in United States Market
Table 5. Top Alzheimer's Disease Therapeutics and Diagnostics Players in United States Market, Ranking by Revenue (2019)
Table 6. United States Alzheimer's Disease Therapeutics and Diagnostics Revenue by Companies, (US$, Mn), 2016-2021
Table 7. United States Alzheimer's Disease Therapeutics and Diagnostics Revenue Share by Companies, 2016-2021
Table 8. Companies Alzheimer's Disease Therapeutics and Diagnostics Product Type
Table 9. List of Tier 1 Alzheimer's Disease Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Alzheimer's Disease Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue (US$, Mn), 2016-2021
Table 13. By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue (US$, Mn), 2022-2027
Table 14. By Application – United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue (US$, Mn), 2016-2021
Table 16. By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue (US$, Mn), 2022-2027
Table 17. Namenda Company Details
Table 18. Namenda Business Overview
Table 19. Namenda Alzheimer's Disease Therapeutics and Diagnostics Product
Table 20. Namenda Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 21. Namenda Recent Developments
Table 22. Aricept Company Details
Table 23. Aricept Business Overview
Table 24. Aricept Alzheimer's Disease Therapeutics and Diagnostics Product
Table 25. Aricept Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 26. Aricept Recent Developments
Table 27. Exelon Company Details
Table 28. Exelon Business Overview
Table 29. Exelon Alzheimer's Disease Therapeutics and Diagnostics Product
Table 30. Exelon Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 31. Exelon Recent Developments
Table 32. Solanezumab Company Details
Table 33. Solanezumab Business Overview
Table 34. Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Product
Table 35. Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 36. Solanezumab Recent Developments
Table 37. Gantenerumab Company Details
Table 38. Gantenerumab Business Overview
Table 39. Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Product
Table 40. Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 41. Gantenerumab Recent Developments
Table 42. Verubecestat Company Details
Table 43. Verubecestat Business Overview
Table 44. Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Product
Table 45. Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 46. Verubecestat Recent Developments
Table 47. Pfizer Company Details
Table 48. Pfizer Business Overview
Table 49. Pfizer Alzheimer's Disease Therapeutics and Diagnostics Product
Table 50. Pfizer Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 51. Pfizer Recent Developments
Table 52. Eisai Company Details
Table 53. Eisai Business Overview
Table 54. Eisai Alzheimer's Disease Therapeutics and Diagnostics Product
Table 55. Eisai Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 56. Eisai Recent Developments
Table 57. Actavis Company Details
Table 58. Actavis Business Overview
Table 59. Actavis Alzheimer's Disease Therapeutics and Diagnostics Product
Table 60. Actavis Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 61. Actavis Recent Developments
Table 62. Lundbeck Company Details
Table 63. Lundbeck Business Overview
Table 64. Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Product
Table 65. Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 66. Lundbeck Recent Developments
Table 67. Daiichi Sankyo Company Details
Table 68. Daiichi Sankyo Business Overview
Table 69. Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Product
Table 70. Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 71. Daiichi Sankyo Recent Developments
Table 72. Novartis Company Details
Table 73. Novartis Business Overview
Table 74. Novartis Alzheimer's Disease Therapeutics and Diagnostics Product
Table 75. Novartis Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 76. Novartis Recent Developments
Table 77. TauRx Company Details
Table 78. TauRx Business Overview
Table 79. TauRx Alzheimer's Disease Therapeutics and Diagnostics Product
Table 80. TauRx Alzheimer's Disease Therapeutics and Diagnostics Revenue in United States Market (2016-2021) & (US$ Million)
Table 81. TauRx Recent Developments
List of Figures
Figure 1. Alzheimer's Disease Therapeutics and Diagnostics Segment by Type
Figure 2. Alzheimer's Disease Therapeutics and Diagnostics Segment by Application
Figure 3. United States Alzheimer's Disease Therapeutics and Diagnostics Market Overview: 2020
Figure 4. United States Alzheimer's Disease Therapeutics and Diagnostics Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. United States Alzheimer's Disease Therapeutics and Diagnostics Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Alzheimer's Disease Therapeutics and Diagnostics Revenue in 2020
Figure 7. By Type - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share, 2016-2027
Figure 8. By Application - United States Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share, 2016-2027
Figure 9. Namenda Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Aricept Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Exelon Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. Pfizer Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Eisai Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 17. Actavis Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 18. Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 19. Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 20. Novartis Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 21. TauRx Alzheimer's Disease Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Keyplayers in United States Alzheimer's Disease Therapeutics and Diagnostics Market Report & Forecast 2021-2027
NamendaAricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
Request Sample
Request Discount
